A case of persistent liver damage in a patient with malignant melanoma caused by immune－related adverse events

Key Points

• The aim is to identify the cause of severe liver damage in a patient with malignant melanoma receiving cancer therapies.
• Reported a case of a 45-year-old female with stage IV malignant melanoma
• Administered immune checkpoint inhibitors nivolumab and ipilimumab
• Monitored liver function post-treatment for adverse events
• Used DLST and liver biopsy to investigate liver damage causes
• Patient developed Grade 3 liver damage three weeks after starting ICI therapy
• Subsequent Grade 4 liver damage occurred four months after targeted therapy initiation
• Liver damage improved with PSL treatment but recurred upon resuming targeted therapy